Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CORBF NASDAQ:DCGO NASDAQ:NAKA NASDAQ:XGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCORBFGlobal Cord Blood$1.35$1.01$0.25▼$2.00$164.09M-0.6102,862 shsN/ADCGODocGo$1.57+12.9%$1.51$1.23▼$5.68$160.11M0.96478,564 shs1.30 million shsNAKAKindlyMD$9.57+27.6%$12.04$0.65▼$34.77$72.79M34.35301,723 shs654,338 shsXGNExagen$9.20+2.3%$7.41$2.38▼$9.21$202.44M1.61427,024 shs166,824 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCORBFGlobal Cord Blood0.00%+90.14%+145.23%+23.85%-10.00%DCGODocGo+12.95%+18.05%+0.64%+11.35%-47.49%NAKAKindlyMD+27.60%+50.71%-22.51%+956,999,900.00%+956,999,900.00%XGNExagen+2.34%+6.60%+34.70%+61.12%+275.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCORBFGlobal Cord BloodN/AN/AN/AN/AN/AN/AN/AN/ADCGODocGo2.6607 of 5 stars3.33.00.00.02.22.50.6NAKAKindlyMDN/AN/AN/AN/AN/AN/AN/AN/AXGNExagen4.1577 of 5 stars3.52.00.04.52.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCORBFGlobal Cord Blood 0.00N/AN/AN/ADCGODocGo 2.50Moderate Buy$3.56126.75% UpsideNAKAKindlyMD 0.00N/AN/AN/AXGNExagen 3.00Buy$11.2522.28% UpsideCurrent Analyst Ratings BreakdownLatest NAKA, XGN, CORBF, and DCGO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025XGNExagenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.007/30/2025XGNExagenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $11.007/30/2025XGNExagenKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSector Weight ➝ Overweight$12.007/23/2025XGNExagenCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.005/15/2025XGNExagenUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025XGNExagenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.005/13/2025XGNExagenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/12/2025DCGODocGoCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$5.00 ➝ $1.455/9/2025DCGODocGoNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.005/9/2025DCGODocGoBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCORBFGlobal Cord Blood$196.12M0.84$0.96 per share1.40N/A∞DCGODocGo$616.55M0.26$0.42 per share3.71$3.09 per share0.51NAKAKindlyMD$2.72M26.77N/AN/A$1.18 per share8.11XGNExagen$55.64M3.64N/AN/A$0.96 per share9.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCORBFGlobal Cord Blood$79.04MN/A0.00∞N/AN/AN/AN/AN/ADCGODocGo$19.99M-$0.020.0019.63N/A-4.20%-3.19%-2.18%N/ANAKAKindlyMD-$3.62M-$0.860.00∞N/A-244.00%-131.09%-106.04%N/AXGNExagen-$15.11M-$0.890.00N/AN/A-28.85%-130.38%-34.69%N/ALatest NAKA, XGN, CORBF, and DCGO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025DCGODocGo-$0.06-$0.11-$0.05-$0.11$77.58 million$80.42 million8/5/2025Q2 2025NAKAKindlyMDN/A-$0.34N/A-$0.35N/A$0.41 million7/29/2025Q2 2025XGNExagen-$0.18-$0.18N/A-$0.21$16.25 million$17.20 million5/12/2025Q1 2025XGNExagen-$0.20-$0.20N/A-$0.20$14.55 million$15.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCORBFGlobal Cord BloodN/AN/AN/AN/AN/ADCGODocGoN/AN/AN/AN/AN/ANAKAKindlyMDN/AN/AN/AN/AN/AXGNExagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCORBFGlobal Cord BloodN/AN/AN/ADCGODocGoN/A2.442.44NAKAKindlyMDN/A13.002.30XGNExagen1.064.954.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCORBFGlobal Cord BloodN/ADCGODocGo56.44%NAKAKindlyMDN/AXGNExagen75.25%Insider OwnershipCompanyInsider OwnershipCORBFGlobal Cord Blood0.50%DCGODocGo2.70%NAKAKindlyMD40.79%XGNExagen12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCORBFGlobal Cord Blood1,200121.55 millionN/ANot OptionableDCGODocGo4,407101.98 million99.23 millionOptionableNAKAKindlyMDN/A7.61 million4.50 millionN/AXGNExagen22022.00 million19.23 millionOptionableNAKA, XGN, CORBF, and DCGO HeadlinesRecent News About These CompaniesExagen Inc. to Participate in Third Quarter Investor ConferencesAugust 6 at 5:13 PM | gurufocus.comExagen Inc. to Participate in Third Quarter Investor ConferencesAugust 6 at 4:05 PM | globenewswire.comExagen Inc. (NASDAQ:XGN) Short Interest Up 144.8% in JulyAugust 4, 2025 | marketbeat.comBTIG Sticks to Their Buy Rating for Exagen (XGN)August 2, 2025 | theglobeandmail.comFY2026 EPS Estimates for Exagen Cut by Cantor FitzgeraldAugust 2, 2025 | marketbeat.comWilliam Blair Has Negative Outlook of Exagen FY2025 EarningsAugust 2, 2025 | marketbeat.comWhat is KeyCorp's Forecast for Exagen Q3 Earnings?August 2, 2025 | marketbeat.comFY2025 Earnings Forecast for Exagen Issued By William BlairAugust 2, 2025 | americanbankingnews.comKeyCorp Predicts Exagen's Q3 Earnings (NASDAQ:XGN)August 2, 2025 | americanbankingnews.comExagen (XGN) Receives a Buy from Craig-HallumAugust 1, 2025 | theglobeandmail.comFY2026 Earnings Forecast for Exagen Issued By KeyCorpAugust 1, 2025 | marketbeat.comExagen Inc. Reports Record Revenue Amidst Growth ChallengesAugust 1, 2025 | theglobeandmail.comCanaccord Genuity Group Raises Exagen (NASDAQ:XGN) Price Target to $11.00August 1, 2025 | americanbankingnews.comExagen (NASDAQ:XGN) Upgraded at KeyCorpAugust 1, 2025 | americanbankingnews.comCanaccord Genuity Sticks to Its Buy Rating for Exagen (XGN)July 31, 2025 | theglobeandmail.comExagen (NASDAQ:XGN) Stock Price Expected to Rise, Canaccord Genuity Group Analyst SaysJuly 31, 2025 | marketbeat.comExagen (NASDAQ:XGN) Upgraded to "Overweight" at KeyCorpJuly 31, 2025 | marketbeat.comXGN | Exagen Inc. Annual Cash Flow Statement | MarketWatchJuly 31, 2025 | marketwatch.comKeybanc Upgrades Exagen (XGN)July 31, 2025 | msn.comExagen (NASDAQ:XGN) Posts Earnings Results, Hits EstimatesJuly 30, 2025 | marketbeat.comExagen upgraded to Overweight from Sector Weight at KeyBancJuly 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNAKA, XGN, CORBF, and DCGO Company DescriptionsGlobal Cord Blood NYSE:CORBF$1.35 0.00 (0.00%) As of 08/8/2025Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.DocGo NASDAQ:DCGO$1.57 +0.18 (+12.95%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.60 +0.03 (+2.23%) As of 08/8/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.KindlyMD NASDAQ:NAKA$9.57 +2.07 (+27.60%) As of 08/8/2025 04:00 PM EasternKindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.Exagen NASDAQ:XGN$9.20 +0.21 (+2.34%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$9.22 +0.02 (+0.16%) As of 08/8/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
